Neuronetics

Q2 FY2026 EarningsQ2 FY26 performance significantly beat consensus across all key profitability metrics despite a modest top-line beat. Revenue reached $41.6M (+9.1% YoY) vs. the $40.2M expected, driven by strong 16.8% growth in the Greenbrook clinic segment. GAAP EPS of -$0.05 beat the -$0.12 consensus by a wide margin, supported by a substantial gross margin expansion to 51.1% (vs. 47.2% expected) and a 12% YoY reduction in operating expenses. Management narrowed FY26 revenue guidance slightly while raising gross margin and operating cash flow expectations.